TDSPHARM Announces Extraordinary General Meeting for June 2026 with Agenda on Articles Amendment and Director Compensation Limit
TDSPHARM will hold an extraordinary general meeting on July 15, 2026, proposing amendments to the articles of incorporation and approval of director compensation limits.
The proposed charter amendments refine the written voting process and establish an annual director compensation cap of KRW 1 billion with performance-linked criteria.
The director compensation limit seeks approval for up to KRW 1 billion for three directors including one outside director, compared to actual payments of approximately KRW 616 million in the prior period.
This EGM is a routine procedural milestone without capital changes or new financing, resulting in no direct dilution or financial impact on shareholder value.
[AI Summary]TDSPHARM's EGM notice involves routine governance updates and compensation approvals without altering capital structure, making the financial impact neutral for shareholders.